Covered recipient · General Payments record
ARSHAD M KHANANI
Allopathic & Osteopathic Physicians Ophthalmology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$312,928.68
203 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $285,955.75 | 101 |
| Travel and Lodging | $21,263.03 | 15 |
| Food and Beverage | $3,309.90 | 86 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,400.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Ocular Therapeutix, Inc. | $81,101.82 | 48 |
| F. Hoffmann-La Roche AG | $80,674.94 | 25 |
| ABBVIE INC. | $51,732.37 | 21 |
| Genentech, Inc. | $17,533.94 | 5 |
| Genentech USA, Inc. | $14,892.52 | 29 |
| Astellas Pharma US Inc | $13,089.01 | 22 |
| SANOFI US SERVICES INC. | $9,765.00 | 2 |
| Alcon Vision LLC | $9,000.00 | 2 |
| Amgen Inc. | $8,400.00 | 3 |
| Astellas Pharma Global Development | $8,138.00 | 3 |
| Apellis Pharmaceuticals, Inc. | $3,292.42 | 3 |
| Regeneron Healthcare Solutions, Inc. | $3,221.00 | 4 |
| Boehringer Ingelheim International GmbH | $2,900.00 | 3 |
| EyePoint Pharmaceuticals US, Inc. | $2,000.00 | 2 |
| Harrow Eye, LLC | $1,630.34 | 4 |
| Janssen Global Services, LLC | $1,500.00 | 3 |
| Regeneron Pharmaceuticals, Inc. | $1,414.96 | 3 |
| Kyowa Kirin, Inc. | $1,201.46 | 7 |
| Samsung Bioepis Co., Ltd. | $1,100.00 | 1 |
| SANOFI-AVENTIS U.S. LLC | $88.50 | 1 |
| Alimera Sciences, Inc. | $71.22 | 3 |
| Bausch & Lomb Americas Inc. | $65.99 | 4 |
| Biogen, Inc. | $51.46 | 2 |
| Astellas Pharma Inc | $24.28 | 1 |
| Thea Pharma Inc. | $22.76 | 1 |
| ANI Pharmaceuticals, Inc. | $16.69 | 1 |
Page 2 of 5; records 51–100 of 203 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ARSHAD M KHANANI
NPI 1295929511 · CMS profile ID 240860
Allopathic & Osteopathic Physicians / Ophthalmology
RENO, NV
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 203 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1295929511?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ARSHAD M KHANANI, NPI 1295929511, CMS profile ID 240860. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 203 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295929511?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ARSHAD M KHANANI, NPI 1295929511, CMS profile ID 240860. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 203 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295929511?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ARSHAD M KHANANI, NPI 1295929511, CMS profile ID 240860, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 203 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1295929511?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
203 matching records · $312,928.68 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 203.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| F. Hoffmann-La Roche AG | $28.24 | 09/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979031 | CMS |
| F. Hoffmann-La Roche AG | $9,687.50 | 09/20/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979035 | CMS |
| F. Hoffmann-La Roche AG | $1,557.14 | 09/20/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979037 | CMS |
| F. Hoffmann-La Roche AG | $48.30 | 09/20/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979039 | CMS |
| F. Hoffmann-La Roche AG | $16.61 | 09/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979043 | CMS |
| F. Hoffmann-La Roche AG | $9,877.61 | 09/20/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979045 | CMS |
| Astellas Pharma Inc | $24.28 | 09/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1128595516 | CMS |
| F. Hoffmann-La Roche AG | $6,450.00 | 09/19/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979033 | CMS |
| F. Hoffmann-La Roche AG | $537.50 | 09/19/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979041 | CMS |
| F. Hoffmann-La Roche AG | $3,225.00 | 09/18/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979047 | CMS |
| Genentech USA, Inc. | $25.26 | 09/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132978979 | CMS |
| Alcon Vision LLC | $6,000.00 | 09/05/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110517966 | CMS |
| SANOFI US SERVICES INC. | $4,743.00 | 09/04/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139933567 | CMS |
| Astellas Pharma US Inc | $30.70 | 09/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139392406 | CMS |
| Bausch & Lomb Americas Inc. | $14.92 | 09/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1140305720 | CMS |
| Genentech USA, Inc. | $32.07 | 08/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132978977 | CMS |
| Ocular Therapeutix, Inc. | $1,200.00 | 08/29/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196717 | CMS |
| Genentech, Inc. | $8,062.50 | 08/28/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132978997 | CMS |
| Ocular Therapeutix, Inc. | $1,200.00 | 08/27/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196685 | CMS |
| Astellas Pharma Global Development | $4,800.00 | 08/21/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132966485 | CMS |
| Genentech USA, Inc. | $27.99 | 08/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132978939 | CMS |
| Genentech USA, Inc. | $5,640.00 | 08/17/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979049 | CMS |
| Genentech USA, Inc. | $20.63 | 08/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132978941 | CMS |
| Ocular Therapeutix, Inc. | $900.00 | 08/14/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196737 | CMS |
| Boehringer Ingelheim International GmbH | $1,000.00 | 08/13/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117954285 | CMS |
| Ocular Therapeutix, Inc. | $1,200.00 | 08/13/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196683 | CMS |
| Ocular Therapeutix, Inc. | $1,200.00 | 08/13/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196735 | CMS |
| Ocular Therapeutix, Inc. | $1,200.00 | 08/13/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196745 | CMS |
| Ocular Therapeutix, Inc. | $4,800.00 | 08/11/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196747 | CMS |
| Ocular Therapeutix, Inc. | $2,400.00 | 08/10/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196741 | CMS |
| Ocular Therapeutix, Inc. | $33.90 | 08/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196775 | CMS |
| Ocular Therapeutix, Inc. | $196.45 | 08/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196773 | CMS |
| Harrow Eye, LLC | $1,400.00 | 08/07/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145606524 | CMS |
| Astellas Pharma US Inc | $20.84 | 08/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139404965 | CMS |
| EyePoint Pharmaceuticals US, Inc. | $500.00 | 08/01/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089508268 | CMS |
| Genentech USA, Inc. | $15.04 | 08/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132978975 | CMS |
| Ocular Therapeutix, Inc. | $4,800.00 | 08/01/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196715 | CMS |
| Ocular Therapeutix, Inc. | $1,800.00 | 07/30/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196731 | CMS |
| Apellis Pharmaceuticals, Inc. | $3,258.00 | 07/26/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154017131 | CMS |
| F. Hoffmann-La Roche AG | $17.01 | 07/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979013 | CMS |
| F. Hoffmann-La Roche AG | $301.67 | 07/19/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979019 | CMS |
| F. Hoffmann-La Roche AG | $9,687.50 | 07/19/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979021 | CMS |
| F. Hoffmann-La Roche AG | $682.03 | 07/19/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979023 | CMS |
| F. Hoffmann-La Roche AG | $6,010.74 | 07/19/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979025 | CMS |
| Apellis Pharmaceuticals, Inc. | $3.17 | 07/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154017129 | CMS |
| F. Hoffmann-La Roche AG | $19.44 | 07/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979015 | CMS |
| F. Hoffmann-La Roche AG | $6,450.00 | 07/18/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132979017 | CMS |
| Ocular Therapeutix, Inc. | $4,200.00 | 07/18/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196709 | CMS |
| Ocular Therapeutix, Inc. | $53.41 | 07/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196763 | CMS |
| Ocular Therapeutix, Inc. | $900.00 | 07/17/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148196721 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $39,148.27 | 18 |
| PY2025 | Principal investigator | $9,440,296.74 | 794 |
| PY2024 | Recipient | $34,748.66 | 38 |
| PY2024 | Principal investigator | $5,811,402.38 | 536 |
| PY2023 | Recipient | $35,655.81 | 9 |
| PY2023 | Principal investigator | $6,631,631.17 | 453 |
| PY2022 | Recipient | $6,696.00 | 7 |
| PY2022 | Principal investigator | $7,057,542.40 | 316 |
| PY2021 | Recipient | $22,062.69 | 14 |
| PY2021 | Principal investigator | $6,270,986.55 | 250 |
| PY2020 | Recipient | $22,048.81 | 12 |
| PY2020 | Principal investigator | $6,171,987.30 | 141 |
| PY2019 | Principal investigator | $2,437,713.74 | 67 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
812 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 12/31/2025 | Non-covered Recipient Entity Sierra Eye Associates-Primary Services Reno | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220771937 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,000.00 | 12/31/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239503 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,939.90 | 12/31/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239505 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $49,562.76 | 12/31/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239507 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $51,821.29 | 12/31/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239509 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $9,629.80 | 12/31/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239511 |
| Principal investigator 1 | Roche TCRC, Inc. | $20,388.00 | 12/31/2025 | Non-covered Recipient Entity Sierra Eye Associates | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211655915 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $16,988.30 | 12/29/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239489 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,850.00 | 12/29/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239491 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $23,870.00 | 12/29/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239493 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,020.40 | 12/29/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239495 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $980.00 | 12/29/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239497 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,000.00 | 12/29/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239499 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,520.00 | 12/29/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239501 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $133,824.60 | 12/24/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239481 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $48,288.20 | 12/24/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239483 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $96,352.20 | 12/24/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239485 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,000.00 | 12/24/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239487 |
| Principal investigator 1 | Genentech, Inc. | $40,216.85 | 12/22/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599758 |
| Principal investigator 1 | Genentech, Inc. | $4,185.00 | 12/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211655824 |
| Principal investigator 1 | Genentech, Inc. | $136.00 | 12/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211655831 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 12/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814771 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 12/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814777 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 12/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814782 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,010.87 | 12/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814789 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,636.74 | 12/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814797 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,892.47 | 12/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814805 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,636.74 | 12/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814816 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 12/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814824 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,010.87 | 12/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814829 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 12/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814837 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,636.74 | 12/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814845 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,010.87 | 12/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814852 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $227,476.20 | 12/19/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239477 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,788.08 | 12/19/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239479 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $55,579.48 | 12/19/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226107505 |
| Principal investigator 1 | Roche TCRC, Inc. | $9,396.70 | 12/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211655894 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $21,559.66 | 12/17/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239475 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,437.14 | 12/17/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226107471 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $18,970.39 | 12/17/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226107489 |
| Principal investigator 1 | Roche TCRC, Inc. | $5,423.80 | 12/16/2025 | Non-covered Recipient Entity Sierra Eye Associates | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211655902 |
| Principal investigator 1 | Janssen Research & Development, LLC | $274.00 | 12/15/2025 | Non-covered Recipient Entity DURANT ET AL | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175427180 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,275.00 | 12/15/2025 | Non-covered Recipient Entity DURANT ET AL | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175427211 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,274.00 | 12/15/2025 | Non-covered Recipient Entity DURANT ET AL | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175427238 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,700.00 | 12/15/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239447 |
| Principal investigator 1 | Genentech, Inc. | $5,170.00 | 12/11/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599724 |
| Principal investigator 1 | Genentech, Inc. | $11,240.00 | 12/11/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599754 |
| Principal investigator 1 | Genentech, Inc. | $149.00 | 12/10/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211655819 |
| Principal investigator 1 | Genentech, Inc. | $3,698.00 | 12/10/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211655828 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $42,238.80 | 12/10/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239473 |
| Principal investigator 1 | Genentech, Inc. | $2,070.00 | 12/09/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599729 |
| Principal investigator 1 | Genentech, Inc. | $18,506.09 | 12/09/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599745 |
| Principal investigator 1 | Genentech, Inc. | $257,090.00 | 12/08/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599872 |
| Principal investigator 1 | Roche TCRC, Inc. | $5,119.00 | 12/08/2025 | Non-covered Recipient Entity Sierra Eye Associates | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211655898 |
| Principal investigator 1 | Roche TCRC, Inc. | $6,895.42 | 12/08/2025 | Non-covered Recipient Entity Sierra Eye Associates | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211655906 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,660.00 | 12/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239457 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,081.80 | 12/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239459 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $24,962.83 | 12/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239461 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,085.15 | 12/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239463 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $11,397.45 | 12/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239465 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $12,320.00 | 12/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239467 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,930.00 | 12/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239469 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,540.00 | 12/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239471 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,700.00 | 12/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211655857 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $29,338.45 | 12/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239453 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $23.91 | 12/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239455 |
| Principal investigator 1 | Genentech, Inc. | $1,199.00 | 12/01/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599733 |
| Principal investigator 1 | Genentech, Inc. | $8,283.00 | 12/01/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599736 |
| Principal investigator 1 | Genentech, Inc. | $1,341.36 | 12/01/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599741 |
| Principal investigator 1 | Genentech, Inc. | $4,242.89 | 12/01/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599749 |
| Principal investigator 1 | Genentech, Inc. | $2,355.00 | 12/01/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599764 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $11,633.02 | 12/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239449 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,850.00 | 12/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239451 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,500.00 | 11/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221814301 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,500.00 | 11/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221814308 |
| Principal investigator 1 | Genentech, Inc. | $1,303.26 | 11/25/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599714 |
| Principal investigator 1 | Genentech, Inc. | $20,350.36 | 11/25/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599858 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,456.00 | 11/24/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1175427315 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,274.00 | 11/24/2025 | Non-covered Recipient Entity DURANT ET AL | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175427337 |
| Principal investigator 1 | Genentech, Inc. | $17,635.56 | 11/21/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599719 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $140.00 | 11/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239433 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $350.00 | 11/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239435 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $97,889.40 | 11/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239437 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $116,291.70 | 11/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239439 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $9,000.00 | 11/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239441 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $47,964.06 | 11/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239443 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $8,425.00 | 11/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239445 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $215.09 | 11/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226107466 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $44,746.94 | 11/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226107483 |
| Principal investigator 1 | ABBVIE INC. | $6,564.16 | 11/20/2025 | Non-covered Recipient Entity DURANT ET AL LTD | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) | No dispute reported | 06/30/2026 | 1202525086 |
| Principal investigator 1 | Genentech, Inc. | $6,066.54 | 11/20/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599868 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.92 | 11/19/2025 | Non-covered Recipient Entity Sierra Eye Associates-Primary Services Reno | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220771939 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $199.80 | 11/19/2025 | Non-covered Recipient Entity Sierra Eye Associates-Primary Services Reno | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220771941 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 11/19/2025 | Non-covered Recipient Entity Sierra Eye Associates-Primary Services Reno | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220771943 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.70 | 11/19/2025 | Non-covered Recipient Entity Sierra Eye Associates-Primary Services Reno | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220771945 |
| Principal investigator 1 | Genentech, Inc. | $71,528.00 | 11/19/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Constance Faricimab in nAMD patients | No dispute reported | 06/30/2026 | 1211599494 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,150.00 | 11/19/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239429 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,685.00 | 11/19/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239431 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 11/18/2025 | Non-covered Recipient Entity Sierra Eye Associates-Primary Services Reno | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220771933 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $95.01 | 11/18/2025 | Non-covered Recipient Entity Sierra Eye Associates-Primary Services Reno | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220771935 |
| Principal investigator 1 | Genentech, Inc. | $17,172.60 | 11/14/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599693 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $36,145.54 | 11/14/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239425 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $20,040.87 | 11/14/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239427 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,200.00 | 11/13/2025 | Non-covered Recipient Entity Sierra Eye Associates | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211655910 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $411.00 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814104 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $750.00 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814112 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $15,138.50 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814121 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,410.25 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814129 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $2,055.00 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814138 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,541.25 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814147 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $645.00 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814157 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,750.00 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814165 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $2,329.00 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814170 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $13,357.50 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814178 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $24,660.00 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814187 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $58.16 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814196 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,720.00 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814206 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $568.68 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814214 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $13,700.00 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814221 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $2,740.00 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814231 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,438.50 | 11/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814239 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,260.00 | 11/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239413 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,334.45 | 11/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239415 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,220.00 | 11/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239417 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,000.00 | 11/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239419 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $11,043.68 | 11/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239421 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $539.00 | 11/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239423 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,987.19 | 11/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226107511 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,007.46 | 11/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226107516 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $205.50 | 11/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226107531 |
| Principal investigator 1 | ABBVIE INC. | $4,060.96 | 11/11/2025 | Non-covered Recipient Entity DURANT ET AL LTD | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202523791 |
| Principal investigator 1 | Genentech, Inc. | $4,900.00 | 11/10/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599865 |
| Principal investigator 1 | Genentech, Inc. | $4,400.00 | 11/07/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599861 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,500.00 | 11/07/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239409 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,060.00 | 11/07/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239411 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $959.00 | 11/07/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226107456 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,810.68 | 11/07/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226107461 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 11/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655801 |
| Principal investigator 1 | Genentech, Inc. | $60,987.00 | 11/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655807 |
| Principal investigator 1 | Genentech, Inc. | $689.00 | 11/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655811 |
| Principal investigator 1 | Genentech, Inc. | $2,400.00 | 11/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655815 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,000.00 | 11/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221814090 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,370.00 | 11/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226107478 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,046.00 | 10/31/2025 | Non-covered Recipient Entity DURANT ET AL | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175427269 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $327,398.40 | 10/29/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239407 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 10/28/2025 | Non-covered Recipient Entity Sierra Eye Associates-Primary Services Reno | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220771931 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,267.27 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812659 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,010.87 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812668 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,705.75 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812678 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,205.61 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812686 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,767.40 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812692 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,469.01 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812713 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,530.66 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812725 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,705.75 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812734 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,767.40 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812741 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,010.87 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812749 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812757 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812765 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,636.74 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812775 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,267.27 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812790 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,469.01 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812798 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,767.40 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812805 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,469.01 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812812 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,010.87 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812819 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812825 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812834 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812841 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,892.47 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812848 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812862 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,267.27 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812869 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,010.87 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812878 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,267.27 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812885 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,636.74 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812891 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,636.74 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812901 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,267.27 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812908 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $2,051.71 | 10/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221812924 |
| Principal investigator 1 | Roche TCRC, Inc. | $13,269.00 | 10/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211655890 |
| Principal investigator 1 | Genentech, Inc. | $5,152.00 | 10/22/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599850 |
| Principal investigator 1 | Genentech, Inc. | $19,166.80 | 10/22/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599853 |
| Principal investigator 1 | Genentech, Inc. | $272.00 | 10/22/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655763 |
| Principal investigator 1 | Genentech, Inc. | $6,549.00 | 10/22/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655794 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $68.50 | 10/22/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221811386 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $102.75 | 10/22/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221811394 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $890.50 | 10/22/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221811401 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 10/22/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221811413 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $10,081.83 | 10/22/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221811422 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $2,571.49 | 10/22/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221811428 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $89,060.30 | 10/22/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239403 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $292,851.00 | 10/22/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239405 |
| Principal investigator 1 | Genentech, Inc. | $18,129.00 | 10/17/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599698 |
| Principal investigator 1 | Genentech, Inc. | $5,890.53 | 10/17/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655760 |
| Principal investigator 1 | Genentech, Inc. | $69.00 | 10/17/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655768 |
| Principal investigator 1 | Genentech, Inc. | $102.00 | 10/17/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655777 |
| Principal investigator 1 | Genentech, Inc. | $1,097.00 | 10/17/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655785 |
| Principal investigator 1 | Genentech, Inc. | $3,905.00 | 10/17/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655796 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,500.00 | 10/17/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239399 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $38,765.20 | 10/17/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239401 |
| Principal investigator 1 | Genentech, Inc. | $11,251.75 | 10/16/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Constance Faricimab in nAMD patients | No dispute reported | 06/30/2026 | 1211599485 |
| Principal investigator 1 | Genentech, Inc. | $3,595.63 | 10/16/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Constance Faricimab in nAMD patients | No dispute reported | 06/30/2026 | 1211599490 |
| Principal investigator 1 | Genentech, Inc. | $3,762.00 | 10/16/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599707 |
| Principal investigator 1 | Genentech, Inc. | $16,156.00 | 10/15/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655789 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,614.52 | 10/15/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239329 |
| Principal investigator 1 | ABBVIE INC. | $5,425.20 | 10/14/2025 | Non-covered Recipient Entity DURANT ET AL LTD | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202516761 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,096.83 | 10/13/2025 | Non-covered Recipient Entity DURANT ET AL | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175427252 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,365.00 | 10/13/2025 | Non-covered Recipient Entity DURANT ET AL | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175427284 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $200.00 | 10/13/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239513 |
| Principal investigator 1 | Genentech, Inc. | $16,568.40 | 10/09/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599703 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,623.68 | 10/08/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239391 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,462.98 | 10/08/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239393 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,001.30 | 10/08/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239395 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,992.98 | 10/08/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239397 |
| Recipient | F. Hoffmann-La Roche AG | $11,872.00 | 10/06/2025 | Covered Recipient Physician | OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD | No dispute reported | 06/30/2026 | 1211534710 |
| Principal investigator 1 | Genentech, Inc. | $165.00 | 10/06/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599683 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $500.00 | 10/06/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221811138 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,746.75 | 10/03/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221811037 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $2,329.00 | 10/03/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221811045 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $205.50 | 10/03/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221811054 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,932.00 | 10/03/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221811063 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,490.00 | 10/03/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221811071 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $66.73 | 10/03/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221811081 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $18,000.00 | 10/03/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221811089 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $15,138.50 | 10/03/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221811096 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $28,770.00 | 10/03/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221811104 |
| Principal investigator 1 | Genentech, Inc. | $18,214.00 | 10/01/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655772 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 10/01/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655780 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $20,040.00 | 10/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239377 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $17,207.36 | 10/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239379 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,483.68 | 10/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239381 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $15,397.43 | 10/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239383 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $20,954.66 | 10/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239385 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,418.00 | 10/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239387 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,195.00 | 10/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239389 |
| Principal investigator 1 | Genentech, Inc. | $822.00 | 09/29/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599669 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $2,800.00 | 09/29/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221810993 |
| Principal investigator 1 | Genentech, Inc. | $16,760.00 | 09/26/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599674 |
| Principal investigator 1 | Genentech, Inc. | $41,701.00 | 09/26/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599687 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 09/26/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427174 |
| Principal investigator 1 | Janssen Research & Development, LLC | $708.00 | 09/26/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427200 |
| Principal investigator 1 | Janssen Research & Development, LLC | $728.00 | 09/26/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427246 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $890.50 | 09/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221810895 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $102.75 | 09/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221810905 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,000.00 | 09/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221810913 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 09/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221810921 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $215.00 | 09/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221810930 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $500.00 | 09/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221810938 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $32,631.04 | 09/26/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239373 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,742.98 | 09/26/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239375 |
| Principal investigator 1 | Genentech, Inc. | $1,400.00 | 09/24/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655662 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,050.00 | 09/24/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239369 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,050.00 | 09/24/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239371 |
| Recipient | F. Hoffmann-La Roche AG | $644.00 | 09/19/2025 | Covered Recipient Physician | A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211534672 |
| Recipient | F. Hoffmann-La Roche AG | $443.92 | 09/19/2025 | Covered Recipient Physician | OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD | No dispute reported | 06/30/2026 | 1211534706 |
| Principal investigator 1 | Genentech, Inc. | $1,943.68 | 09/17/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655678 |
| Principal investigator 1 | Genentech, Inc. | $1,165.00 | 09/17/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655697 |
| Principal investigator 1 | Genentech, Inc. | $823.00 | 09/17/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655707 |
| Principal investigator 1 | Genentech, Inc. | $14,022.00 | 09/17/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655722 |
| Principal investigator 1 | Genentech, Inc. | $51.00 | 09/17/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655729 |
| Principal investigator 1 | Genentech, Inc. | $69.00 | 09/17/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655738 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,500.00 | 09/15/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221810596 |
| Principal investigator 1 | Genentech, Inc. | $1,902.00 | 09/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655621 |
| Principal investigator 1 | Genentech, Inc. | $1,165.00 | 09/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655627 |
| Principal investigator 1 | Genentech, Inc. | $207.00 | 09/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655651 |
| Principal investigator 1 | Genentech, Inc. | $3,535.00 | 09/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655682 |
| Principal investigator 1 | Genentech, Inc. | $480.00 | 09/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655689 |
| Principal investigator 1 | Genentech, Inc. | $102.00 | 09/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655693 |
| Principal investigator 1 | Genentech, Inc. | $891.00 | 09/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655700 |
| Principal investigator 1 | Genentech, Inc. | $1,987.19 | 09/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655742 |
| Principal investigator 1 | Genentech, Inc. | $1,987.19 | 09/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655756 |
| Principal investigator 1 | Janssen Research & Development, LLC | $708.00 | 09/12/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427186 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50.65 | 09/12/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427261 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,000.00 | 09/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239367 |
| Principal investigator 1 | Genentech, Inc. | $4,388.00 | 09/10/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Constance Faricimab in nAMD patients | No dispute reported | 06/30/2026 | 1211599478 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $500.00 | 09/10/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221810471 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $500.00 | 09/10/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221810478 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,000.00 | 09/10/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221810486 |
| Principal investigator 1 | ABBVIE INC. | $5,229.03 | 09/09/2025 | Non-covered Recipient Entity DURANT ET AL LTD | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) | No dispute reported | 06/30/2026 | 1202510350 |
| Principal investigator 1 | ABBVIE INC. | $4,522.73 | 09/09/2025 | Non-covered Recipient Entity DURANT ET AL LTD | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) | No dispute reported | 06/30/2026 | 1202510352 |
| Principal investigator 1 | ABBVIE INC. | $6,216.15 | 09/09/2025 | Non-covered Recipient Entity DURANT ET AL LTD | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) | No dispute reported | 06/30/2026 | 1202510364 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $11,812.06 | 09/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239353 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $32,410.40 | 09/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239355 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $16,064.60 | 09/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239357 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $20,461.04 | 09/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239359 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $35,280.02 | 09/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239361 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $910.00 | 09/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239363 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $35,225.26 | 09/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239365 |
| Principal investigator 1 | Genentech, Inc. | $9,000.00 | 09/04/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599676 |
| Principal investigator 1 | Genentech, Inc. | $1,311.00 | 09/03/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655654 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $880.00 | 09/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239331 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,259.30 | 09/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239333 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,000.00 | 09/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239335 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $18,360.00 | 09/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239337 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $25,730.60 | 09/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239339 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,290.00 | 09/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239341 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,150.00 | 09/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239343 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,353.55 | 09/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239345 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,320.00 | 09/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239347 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $266.17 | 09/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239349 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $880.00 | 09/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239351 |
| Principal investigator 1 | ABBVIE INC. | $29,468.70 | 09/02/2025 | Non-covered Recipient Entity DURANT ET AL LTD | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) | No dispute reported | 06/30/2026 | 1202507031 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $11,561.43 | 09/01/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221810434 |
| Recipient | F. Hoffmann-La Roche AG | $565.91 | 08/29/2025 | Covered Recipient Physician | Faricimab DME Long Term Extension Rhone X | No dispute reported | 06/30/2026 | 1211534676 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $69,426.00 | 08/29/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239327 |
| Principal investigator 1 | ABBVIE INC. | $6,374.61 | 08/27/2025 | Non-covered Recipient Entity DURANT ET AL LTD | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202506129 |
| Principal investigator 1 | ABBVIE INC. | $1,294.65 | 08/27/2025 | Non-covered Recipient Entity DURANT ET AL LTD | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202506147 |
| Principal investigator 1 | ABBVIE INC. | $8,310.42 | 08/27/2025 | Non-covered Recipient Entity DURANT ET AL LTD | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202506149 |
| Principal investigator 1 | ABBVIE INC. | $19,493.73 | 08/27/2025 | Non-covered Recipient Entity DURANT ET AL LTD | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202506193 |
| Principal investigator 1 | Genentech, Inc. | $8,554.04 | 08/27/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599665 |
| Principal investigator 1 | Genentech, Inc. | $13,019.86 | 08/27/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599680 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,100.00 | 08/27/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239325 |
| Principal investigator 1 | Genentech, Inc. | $9,000.00 | 08/22/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599689 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,500.00 | 08/22/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221809726 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $350.00 | 08/22/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239321 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,050.00 | 08/22/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239323 |
| Principal investigator 1 | Genentech, Inc. | $4,672.00 | 08/20/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599846 |
| Principal investigator 1 | Genentech, Inc. | $1,311.00 | 08/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655638 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,000.00 | 08/20/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239309 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $23,260.00 | 08/20/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239311 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $151,700.40 | 08/20/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239313 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,377.00 | 08/20/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239315 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $49,947.90 | 08/20/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239317 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,000.00 | 08/20/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239319 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,600.00 | 08/20/2025 | Non-covered Recipient Entity Sierra Eye Associates | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211655854 |
| Principal investigator 1 | Genentech, Inc. | $25,041.00 | 08/15/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Constance Faricimab in nAMD patients | No dispute reported | 06/30/2026 | 1211599481 |
| Principal investigator 1 | Genentech, Inc. | $11,334.00 | 08/15/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655665 |
| Principal investigator 1 | Genentech, Inc. | $204.00 | 08/15/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655733 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $13,020.00 | 08/15/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239307 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,000.00 | 08/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221809582 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,000.00 | 08/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221809594 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,048.69 | 08/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221809600 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 08/13/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221809527 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $890.50 | 08/13/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221809537 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $205.50 | 08/13/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221809544 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,960.00 | 08/13/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239301 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,000.00 | 08/13/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239303 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $37,985.30 | 08/13/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239305 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,679.80 | 08/13/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085587 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 08/08/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085579 |
| Principal investigator 1 | Genentech, Inc. | $1,010.00 | 08/06/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655657 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $72.74 | 08/06/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239297 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $233.60 | 08/06/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239299 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,436.00 | 08/04/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427219 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,469.01 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808449 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808457 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,636.74 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808462 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,672.46 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808470 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,636.74 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808479 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,469.01 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808484 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,469.01 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808491 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,672.46 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808499 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808508 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,469.01 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808515 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,469.01 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808522 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,491.67 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808528 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,705.75 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808536 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,705.75 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808545 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808551 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,469.01 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808559 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,672.46 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808571 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,491.67 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808578 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,491.67 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808586 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,672.46 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808592 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,672.46 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808598 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,672.46 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808607 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,469.01 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808615 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,469.01 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808623 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,205.61 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808637 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,469.01 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808645 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,491.67 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808651 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,491.67 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808659 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,010.87 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808667 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,491.67 | 08/04/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221808675 |
| Recipient | F. Hoffmann-La Roche AG | $533.33 | 08/01/2025 | Covered Recipient Physician | Faricimab DME Long Term Extension Rhone X | No dispute reported | 06/30/2026 | 1211534702 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $15,429.11 | 08/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239295 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,482.61 | 07/30/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221807760 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,482.61 | 07/30/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221807768 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,844.42 | 07/30/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221807777 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,390.14 | 07/30/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221807783 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,500.00 | 07/30/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239293 |
| Recipient | F. Hoffmann-La Roche AG | $421.25 | 07/29/2025 | Covered Recipient Physician | Comparison of Diabetic Retinopathy Progression With 7 Field and Ultrawide Imaging in the Phase 3 YOSEMITE/RHINE Studies | No dispute reported | 06/30/2026 | 1211534718 |
| Principal investigator 1 | Genentech, Inc. | $2,150.00 | 07/29/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599661 |
| Principal investigator 1 | Genentech, Inc. | $10,415.65 | 07/28/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599827 |
| Principal investigator 1 | Genentech, Inc. | $101,433.00 | 07/28/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599842 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,688.00 | 07/28/2025 | Non-covered Recipient Entity DURANT ET AL | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175427234 |
| Principal investigator 1 | ABBVIE INC. | $5,305.00 | 07/25/2025 | Non-covered Recipient Entity DURANT ET AL LTD | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202499806 |
| Principal investigator 1 | ABBVIE INC. | $3,263.83 | 07/25/2025 | Non-covered Recipient Entity DURANT ET AL LTD | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202499808 |
| Principal investigator 1 | ABBVIE INC. | $6,295.72 | 07/25/2025 | Non-covered Recipient Entity DURANT ET AL LTD | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202499818 |
| Principal investigator 1 | Genentech, Inc. | $7,869.00 | 07/25/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599824 |
| Principal investigator 1 | Genentech, Inc. | $3,253.12 | 07/25/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599836 |
| Principal investigator 1 | Genentech, Inc. | $25,331.00 | 07/25/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655647 |
| Principal investigator 1 | Genentech, Inc. | $272.00 | 07/25/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655672 |
| Principal investigator 1 | Genentech, Inc. | $6,942.00 | 07/25/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655686 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $16,955.30 | 07/25/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239285 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $8,317.65 | 07/25/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239287 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $22,200.30 | 07/25/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239289 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,657.40 | 07/25/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239291 |
| Principal investigator 1 | Genentech, Inc. | $2,200.00 | 07/24/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599832 |
| Principal investigator 1 | Genentech, Inc. | $1,851.00 | 07/23/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655669 |
| Principal investigator 1 | Genentech, Inc. | $136.00 | 07/23/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655714 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,000.00 | 07/23/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221807170 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $133,347.60 | 07/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239279 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $151,258.50 | 07/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239281 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $500.00 | 07/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239283 |
| Principal investigator 1 | Genentech, Inc. | $2,877.00 | 07/21/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599839 |
| Principal investigator 1 | Genentech, Inc. | $24,770.00 | 07/18/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655703 |
| Principal investigator 1 | Genentech, Inc. | $138.00 | 07/18/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655718 |
| Principal investigator 1 | Genentech, Inc. | $2,151.00 | 07/18/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655745 |
| Principal investigator 1 | Genentech, Inc. | $153.00 | 07/18/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655749 |
| Principal investigator 1 | Genentech, Inc. | $686.00 | 07/18/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655752 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,285.46 | 07/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239271 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,200.00 | 07/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239273 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,500.00 | 07/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239275 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $695.38 | 07/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239277 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $225.00 | 07/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085575 |
| Principal investigator 1 | Genentech, Inc. | $44,356.00 | 07/16/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655634 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,561.15 | 07/16/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239261 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,701.15 | 07/16/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239263 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $17,590.00 | 07/16/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239265 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $20,435.30 | 07/16/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239267 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,425.00 | 07/16/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239269 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,837.57 | 07/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221806894 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,477.00 | 07/11/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239259 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $46,719.74 | 07/11/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085583 |
| Principal investigator 1 | Genentech, Inc. | $1,622.00 | 07/09/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655643 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $500.00 | 07/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239253 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $22.02 | 07/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239255 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $277.00 | 07/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239257 |
| Principal investigator 1 | Genentech, Inc. | $71,892.00 | 07/07/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599658 |
| Principal investigator 1 | Janssen Research & Development, LLC | $274.00 | 07/07/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427126 |
| Principal investigator 1 | Janssen Research & Development, LLC | $923.00 | 07/07/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427131 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,436.00 | 07/04/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427323 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $12,385.30 | 07/04/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239249 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,404.38 | 07/04/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239251 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 07/03/2025 | Non-covered Recipient Entity DURANT ET AL | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175427330 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 07/02/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221806838 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $68.50 | 07/02/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221806846 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $102.75 | 07/02/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221806852 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $890.50 | 07/02/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221806861 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $101.94 | 07/02/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239235 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,987.65 | 07/02/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239237 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,500.00 | 07/02/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239239 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $8.30 | 07/02/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239241 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,006.00 | 07/02/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239243 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,905.00 | 07/02/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239245 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $74,008.20 | 07/02/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239247 |
| Principal investigator 1 | Genentech, Inc. | $22,973.37 | 07/01/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Constance Faricimab in nAMD patients | No dispute reported | 06/30/2026 | 1211599470 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $300.00 | 07/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085560 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $300.00 | 07/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085563 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $150.00 | 07/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085567 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 07/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085571 |
| Recipient | F. Hoffmann-La Roche AG | $306.36 | 06/30/2025 | Covered Recipient Physician | OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD | No dispute reported | 06/30/2026 | 1211534714 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $10,362.68 | 06/30/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221806831 |
| Recipient | Ocular Therapeutix, Inc. | $10,469.62 | 06/30/2025 | Covered Recipient Physician | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250229172 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 06/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221806761 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $890.50 | 06/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221806769 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $102.75 | 06/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221806777 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,750.00 | 06/26/2025 | Non-covered Recipient Entity Sierra Eye Associates | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211655842 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,833.50 | 06/26/2025 | Non-covered Recipient Entity Sierra Eye Associates | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211655850 |
| Principal investigator 1 | Genentech, Inc. | $11,598.00 | 06/25/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599499 |
| Principal investigator 1 | Genentech, Inc. | $35,110.00 | 06/25/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599503 |
| Principal investigator 1 | Genentech, Inc. | $129,180.00 | 06/25/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599529 |
| Principal investigator 1 | Genentech, Inc. | $2,192.00 | 06/25/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599533 |
| Principal investigator 1 | Genentech, Inc. | $1,425.00 | 06/25/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599554 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 06/25/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655551 |
| Principal investigator 1 | Genentech, Inc. | $40,324.00 | 06/23/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599507 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $22,110.00 | 06/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239189 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $20,300.00 | 06/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239191 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,796.00 | 06/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239193 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $18,262.95 | 06/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239195 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,993.15 | 06/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239197 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,000.00 | 06/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239199 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,015.00 | 06/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239201 |
| Principal investigator 1 | Genentech, Inc. | $9,565.00 | 06/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655560 |
| Principal investigator 1 | Genentech, Inc. | $272.00 | 06/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655571 |
| Principal investigator 1 | Genentech, Inc. | $171.00 | 06/18/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599521 |
| Principal investigator 1 | Genentech, Inc. | $5,179.12 | 06/18/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599549 |
| Principal investigator 1 | Genentech, Inc. | $25,949.34 | 06/18/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599771 |
| Principal investigator 1 | Genentech, Inc. | $50,598.98 | 06/18/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599779 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,490.00 | 06/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239177 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $385,559.10 | 06/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239179 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,573.15 | 06/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239181 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $39,545.95 | 06/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239183 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,790.80 | 06/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239185 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $18.55 | 06/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239187 |
| Principal investigator 1 | Genentech, Inc. | $9,345.63 | 06/17/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599789 |
| Principal investigator 1 | Genentech, Inc. | $18,006.01 | 06/17/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599793 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $10,150.00 | 06/13/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239175 |
| Principal investigator 1 | Genentech, Inc. | $3,626.36 | 06/12/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599541 |
| Principal investigator 1 | Genentech, Inc. | $6,553.00 | 06/11/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599516 |
| Principal investigator 1 | Genentech, Inc. | $23,980.00 | 06/11/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599773 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 06/11/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655609 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,930.00 | 06/11/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239157 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $11,602.03 | 06/11/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239159 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,420.00 | 06/11/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239161 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,500.00 | 06/11/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239163 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $420.00 | 06/11/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239165 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,807.19 | 06/11/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239167 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,000.00 | 06/11/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239169 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,690.00 | 06/11/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239171 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $20,790.00 | 06/11/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239173 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,132.00 | 06/09/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427161 |
| Principal investigator 1 | Janssen Research & Development, LLC | $364.00 | 06/06/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427289 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $32,340.00 | 06/06/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239153 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $29,264.00 | 06/06/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239155 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,783.79 | 06/04/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085545 |
| Principal investigator 1 | Genentech, Inc. | $21,540.57 | 06/02/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599545 |
| Principal investigator 1 | Genentech, Inc. | $81,856.00 | 06/02/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599783 |
| Principal investigator 1 | Janssen Research & Development, LLC | $182.00 | 06/02/2025 | Non-covered Recipient Entity DURANT ET AL | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175427138 |
| Principal investigator 1 | Janssen Research & Development, LLC | $36.34 | 06/02/2025 | Non-covered Recipient Entity DURANT ET AL | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175427301 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 05/29/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221806183 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $685.00 | 05/29/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221806194 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,233.00 | 05/29/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221806202 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,014.50 | 05/29/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221806208 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 05/29/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221806216 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $13,700.00 | 05/29/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221806223 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $924.75 | 05/29/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221806231 |
| Principal investigator 1 | Genentech, Inc. | $5,886.04 | 05/28/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599512 |
| Principal investigator 1 | Genentech, Inc. | $5,886.04 | 05/28/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599537 |
| Principal investigator 1 | Genentech, Inc. | $162.00 | 05/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655576 |
| Principal investigator 1 | Genentech, Inc. | $3,812.00 | 05/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655590 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 05/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221805901 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $10,396.93 | 05/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221805911 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $102.75 | 05/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221805921 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,789.52 | 05/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221805927 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $68.50 | 05/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221805937 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $890.50 | 05/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221805946 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $86,209.20 | 05/28/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239149 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $30.42 | 05/28/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239151 |
| Principal investigator 1 | Genentech, Inc. | $2,695.33 | 05/21/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599525 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $10,895.00 | 05/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239137 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $82.00 | 05/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239139 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $17,326.00 | 05/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239141 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $880.00 | 05/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239143 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $8,707.19 | 05/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239145 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $39,464.00 | 05/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239147 |
| Principal investigator 1 | Genentech, Inc. | $1,392.07 | 05/20/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599619 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,500.00 | 05/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221805735 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 05/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221805740 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $102.75 | 05/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221805746 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $890.50 | 05/19/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221805756 |
| Principal investigator 1 | Genentech, Inc. | $3,300.00 | 05/15/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599812 |
| Principal investigator 1 | Genentech, Inc. | $1,345.76 | 05/14/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599633 |
| Principal investigator 1 | Genentech, Inc. | $207.00 | 05/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655556 |
| Principal investigator 1 | Genentech, Inc. | $3,097.24 | 05/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655581 |
| Principal investigator 1 | Genentech, Inc. | $951.00 | 05/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655584 |
| Principal investigator 1 | Genentech, Inc. | $685.00 | 05/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655598 |
| Principal investigator 1 | Genentech, Inc. | $5,570.00 | 05/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655604 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,530.00 | 05/14/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239127 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $10,780.00 | 05/14/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239129 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $18.83 | 05/14/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239131 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,775.00 | 05/14/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239133 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $16,698.76 | 05/14/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239135 |
| Recipient | F. Hoffmann-La Roche AG | $668.00 | 05/11/2025 | Covered Recipient Physician | Faricimab DME Long Term Extension Rhone X | No dispute reported | 06/30/2026 | 1211534689 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $10,134.38 | 05/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239117 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,598.40 | 05/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239119 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $8,795.00 | 05/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239121 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $411.00 | 05/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239123 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $11,297.78 | 05/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239125 |
| Recipient | F. Hoffmann-La Roche AG | $335.71 | 05/08/2025 | Covered Recipient Physician | VA2 PhIII Yosemite | No dispute reported | 06/30/2026 | 1211534692 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,274.00 | 05/08/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427167 |
| Principal investigator 1 | Roche TCRC, Inc. | $2,840.00 | 05/08/2025 | Non-covered Recipient Entity Sierra Eye Associates | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211655838 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,980.00 | 05/07/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239107 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,520.00 | 05/07/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239109 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $18,000.00 | 05/07/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239111 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $9,248.00 | 05/07/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239113 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,312.00 | 05/07/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239115 |
| Recipient | F. Hoffmann-La Roche AG | $7,232.43 | 05/05/2025 | Covered Recipient Physician | A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211534681 |
| Recipient | F. Hoffmann-La Roche AG | $266.56 | 05/05/2025 | Covered Recipient Physician | Faricimab DME Long Term Extension Rhone X | No dispute reported | 06/30/2026 | 1211534696 |
| Principal investigator 1 | Janssen Research & Development, LLC | $215.00 | 05/02/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427151 |
| Principal investigator 1 | Genentech, Inc. | $56,246.00 | 05/01/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655548 |
| Principal investigator 1 | Genentech, Inc. | $11,332.00 | 05/01/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655564 |
| Principal investigator 1 | Genentech, Inc. | $204.00 | 05/01/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655568 |
| Principal investigator 1 | Genentech, Inc. | $23,362.00 | 05/01/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655594 |
| Principal investigator 1 | Genentech, Inc. | $476.00 | 05/01/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655601 |
| Principal investigator 1 | Genentech, Inc. | $7,643.00 | 05/01/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655612 |
| Principal investigator 1 | Genentech, Inc. | $10,334.00 | 05/01/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655615 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 05/01/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085540 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $62,943.30 | 04/30/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239103 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,077.00 | 04/30/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239105 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,010.87 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221803880 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,055.96 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221804004 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221804035 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $102.75 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221804043 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $7,490.47 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221804049 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,390.14 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221804057 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,469.01 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221804065 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,491.67 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221804074 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,672.46 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221804082 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $800.00 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221804090 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $890.50 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221804098 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,500.00 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221804107 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,636.74 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221804113 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,205.61 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221804120 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,705.75 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221804128 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,268.61 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221804137 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,469.01 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221804145 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,010.87 | 04/28/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221804154 |
| Principal investigator 1 | Genentech, Inc. | $1,303.26 | 04/25/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599612 |
| Principal investigator 1 | Genentech, Inc. | $2,287.90 | 04/23/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599636 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $8,470.00 | 04/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239099 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,850.00 | 04/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239101 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $36,572.15 | 04/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085552 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,213.20 | 04/23/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085556 |
| Principal investigator 1 | Genentech, Inc. | $5,598.74 | 04/18/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599609 |
| Principal investigator 1 | Genentech, Inc. | $28,824.52 | 04/18/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599640 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,000.00 | 04/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239093 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $8,795.00 | 04/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239095 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $29,923.76 | 04/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239097 |
| Principal investigator 1 | Roche TCRC, Inc. | $708.00 | 04/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211655878 |
| Principal investigator 1 | Roche TCRC, Inc. | $103.00 | 04/18/2025 | Non-covered Recipient Entity Sierra Eye Associates | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211655883 |
| Principal investigator 1 | Roche TCRC, Inc. | $12,400.00 | 04/17/2025 | Non-covered Recipient Entity Sierra Eye Associates | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211655846 |
| Principal investigator 1 | Roche TCRC, Inc. | $9,700.00 | 04/17/2025 | Non-covered Recipient Entity Sierra Eye Associates | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211655887 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,455.23 | 04/16/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239087 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $33,663.40 | 04/16/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239089 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,500.00 | 04/16/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239091 |
| Recipient | F. Hoffmann-La Roche AG | $644.00 | 04/14/2025 | Covered Recipient Physician | A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211534668 |
| Principal investigator 1 | Genentech, Inc. | $5,480.00 | 04/11/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599623 |
| Principal investigator 1 | Genentech, Inc. | $87,003.00 | 04/11/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599647 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,310.00 | 04/11/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239083 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $17,710.00 | 04/11/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239085 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $14,835.72 | 04/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239061 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,500.00 | 04/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239063 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,500.00 | 04/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239065 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $684.40 | 04/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239067 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,500.00 | 04/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239069 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,234.00 | 04/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239071 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $490.00 | 04/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239073 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $10,000.00 | 04/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239075 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,320.00 | 04/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239077 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,000.00 | 04/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239079 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $220.00 | 04/09/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239081 |
| Principal investigator 1 | Genentech, Inc. | $3,595.08 | 04/08/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599651 |
| Principal investigator 1 | Genentech, Inc. | $7,000.00 | 04/08/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON COHEN ET | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211599884 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $17,758.76 | 04/04/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239059 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 04/03/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON COHEN ET | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211599889 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $19,775.00 | 04/02/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239045 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $17,500.24 | 04/02/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239047 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $14,315.57 | 04/02/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239049 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $479.00 | 04/02/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239051 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $22,775.00 | 04/02/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239053 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,980.05 | 04/02/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239055 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $23,420.24 | 04/02/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239057 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,117.25 | 04/01/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802710 |
| Recipient | F. Hoffmann-La Roche AG | $937.00 | 03/31/2025 | Covered Recipient Physician | Four-Year Outcomes of Faricimab in DME: Safety and Efficacy Results From The RHONE-X Long-Term Extension Trial | No dispute reported | 06/30/2026 | 1211534721 |
| Recipient | F. Hoffmann-La Roche AG | $565.91 | 03/31/2025 | Covered Recipient Physician | Clinical Features of Eyes that Participated in the RHONE-X Trial | No dispute reported | 06/30/2026 | 1211534725 |
| Recipient | F. Hoffmann-La Roche AG | $668.00 | 03/31/2025 | Covered Recipient Physician | Four-Year Outcomes of Faricimab in DME: First Time Safety and Efficacy Results From The RHONE-X Long-Term Extension Trial | No dispute reported | 06/30/2026 | 1211534732 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 03/31/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427227 |
| Recipient | F. Hoffmann-La Roche AG | $405.77 | 03/30/2025 | Covered Recipient Physician | OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD | No dispute reported | 06/30/2026 | 1211534685 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,000.00 | 03/28/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239221 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $13,338.00 | 03/28/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239223 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $8,326.28 | 03/28/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239225 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $13,338.00 | 03/28/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239227 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,418.00 | 03/28/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239229 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $215.00 | 03/28/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239231 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $20,701.48 | 03/28/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239233 |
| Principal investigator 1 | Genentech, Inc. | $200.00 | 03/27/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599654 |
| Principal investigator 1 | Genentech, Inc. | $70,392.00 | 03/26/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599614 |
| Principal investigator 1 | Genentech, Inc. | $1,425.00 | 03/26/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599630 |
| Principal investigator 1 | Genentech, Inc. | $3,609.69 | 03/21/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599602 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 03/21/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599606 |
| Principal investigator 1 | Genentech, Inc. | $1,686.99 | 03/21/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599627 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $216,273.60 | 03/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239219 |
| Principal investigator 1 | Genentech, Inc. | $14,773.92 | 03/20/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599643 |
| Principal investigator 1 | Genentech, Inc. | $11,242.14 | 03/20/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599816 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 03/20/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599821 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $500.00 | 03/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802309 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,220.00 | 03/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802315 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 03/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802322 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,500.00 | 03/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802332 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $10,396.93 | 03/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802340 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $411.00 | 03/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802349 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $719.25 | 03/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802358 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $10,396.93 | 03/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802364 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,000.00 | 03/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802371 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $959.00 | 03/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802379 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $10,396.93 | 03/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802386 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,233.50 | 03/20/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221802396 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $343.00 | 03/19/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239217 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $22,089.48 | 03/14/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239215 |
| Principal investigator 1 | Genentech, Inc. | $150.00 | 03/13/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON COHEN ET | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211599876 |
| Principal investigator 1 | Genentech, Inc. | $225.00 | 03/13/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON COHEN ET | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211599881 |
| Principal investigator 1 | Genentech, Inc. | $21,831.00 | 03/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655545 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $12,956.77 | 03/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239211 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $31,954.50 | 03/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239213 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,379.68 | 03/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085532 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,200.00 | 03/10/2025 | Non-covered Recipient Entity Sierra Eye Associates | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211655860 |
| Principal investigator 1 | Genentech, Inc. | $204.00 | 03/07/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655518 |
| Principal investigator 1 | Genentech, Inc. | $9,772.00 | 03/07/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655521 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $21,878.59 | 03/07/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239209 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 03/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801712 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $6,677.93 | 03/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801719 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,705.13 | 03/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801725 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,809.36 | 03/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801731 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,168.63 | 03/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801739 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $102.75 | 03/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801748 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,517.67 | 03/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801760 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,716.88 | 03/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801767 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $890.50 | 03/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801775 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,482.61 | 03/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221801782 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $891.00 | 03/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239203 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $9,236.38 | 03/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239205 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,000.00 | 03/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239207 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,284.00 | 03/03/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427296 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,237.00 | 03/03/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085536 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 02/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655495 |
| Principal investigator 1 | Genentech, Inc. | $81.00 | 02/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655505 |
| Principal investigator 1 | Genentech, Inc. | $1,095.00 | 02/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655529 |
| Principal investigator 1 | Genentech, Inc. | $812.00 | 02/26/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655536 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,000.00 | 02/25/2025 | Non-covered Recipient Entity Sierra Eye Associates | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226085528 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,060.00 | 02/24/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427205 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,200.00 | 02/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211655863 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,500.00 | 02/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211655875 |
| Principal investigator 1 | Genentech, Inc. | $33,113.28 | 02/19/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599808 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $8,290.24 | 02/19/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239039 |
| Principal investigator 1 | Genentech, Inc. | $1,303.26 | 02/18/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599558 |
| Principal investigator 1 | Genentech, Inc. | $25,196.36 | 02/18/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599578 |
| Principal investigator 1 | Genentech, Inc. | $6,871.68 | 02/18/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599599 |
| Principal investigator 1 | Genentech, Inc. | $124,137.00 | 02/18/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599798 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $685.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800882 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,781.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800891 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $205.50 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800899 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $9,247.50 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800907 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $3,318.14 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800912 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $9,247.50 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800922 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $9,316.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800926 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,126.44 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800933 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $2,740.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800941 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,000.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800949 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,544.29 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800957 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $205.50 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800963 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $2,740.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800972 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $274.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800980 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,000.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800987 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $68.50 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800991 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $9,247.50 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801000 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $560.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801006 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,781.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801011 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $274.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801019 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,343.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801026 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $2,740.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801033 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801040 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801047 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $2,740.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801054 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801062 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $50.91 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801070 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $616.50 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801077 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $274.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801085 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $822.00 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801094 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $68.50 | 02/14/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221801100 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $141,079.50 | 02/14/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239037 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,365.00 | 02/13/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427145 |
| Principal investigator 1 | Genentech, Inc. | $1,400.00 | 02/12/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655533 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $31,605.59 | 02/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239031 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,371.24 | 02/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239033 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $46,682.00 | 02/12/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239035 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $70,050.35 | 02/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) | No dispute reported | 06/30/2026 | 1185549157 |
| Principal investigator 1 | Genentech, Inc. | $770.00 | 02/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655491 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 02/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655514 |
| Principal investigator 1 | Genentech, Inc. | $13,669.00 | 02/05/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655526 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $32,380.20 | 02/05/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239025 |
| Principal investigator 1 | Genentech, Inc. | $6,000.00 | 02/04/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD | No dispute reported | 06/30/2026 | 1211599473 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,154.00 | 02/03/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427279 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,260.00 | 02/03/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427308 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,500.00 | 01/31/2025 | Non-covered Recipient Entity DURANT ET AL | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175427192 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 01/30/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221800635 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $68.50 | 01/30/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221800641 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $890.50 | 01/30/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221800650 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $102.75 | 01/30/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221800654 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,919.24 | 01/29/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239043 |
| Principal investigator 1 | Genentech, Inc. | $6,633.04 | 01/28/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211599562 |
| Principal investigator 1 | Genentech, Inc. | $6,898.84 | 01/28/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211599566 |
| Principal investigator 1 | Genentech, Inc. | $1,401.33 | 01/28/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599594 |
| Principal investigator 1 | Genentech, Inc. | $42,886.08 | 01/28/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | MAD to assess the safety tolerability and PK PD in nAMD patients | No dispute reported | 06/30/2026 | 1211599803 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,327.79 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221799922 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $205.50 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221799930 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $4,538.67 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221799941 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $890.50 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221799948 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221799964 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221799968 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,105.85 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221799977 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,426.43 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221799999 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800007 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $2,740.00 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800016 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $7,238.94 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800023 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $8,322.75 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800041 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $890.50 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800049 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $137.00 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800057 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $5,105.85 | 01/27/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1221800062 |
| Principal investigator 1 | Genentech, Inc. | $77,283.00 | 01/24/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655501 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,193.24 | 01/24/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239041 |
| Principal investigator 1 | Roche TCRC, Inc. | $163.64 | 01/24/2025 | Non-covered Recipient Entity Sierra Eye Associates | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211655871 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,000.00 | 01/22/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239027 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,097.24 | 01/22/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239029 |
| Principal investigator 1 | Genentech, Inc. | $1,583.15 | 01/21/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599581 |
| Principal investigator 1 | Roche TCRC, Inc. | $45,114.00 | 01/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211655835 |
| Principal investigator 1 | Roche TCRC, Inc. | $32,421.00 | 01/21/2025 | Non-covered Recipient Entity Sierra Eye Associates | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211655867 |
| Recipient | Novartis Pharmaceuticals Corporation | $2,168.50 | 01/17/2025 | Covered Recipient Physician | CRTH258A2301 | No dispute reported | 06/30/2026 | 1190292741 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,234.24 | 01/17/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239021 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,175.24 | 01/17/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239023 |
| Principal investigator 1 | Genentech, Inc. | $5,323.71 | 01/14/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599574 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,000.00 | 01/13/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239017 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,706.05 | 01/13/2025 | Non-covered Recipient Entity Sierra Eye Associates | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250239019 |
| Principal investigator 1 | Genentech, Inc. | $2,688.11 | 01/10/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599571 |
| Principal investigator 1 | Genentech, Inc. | $259.62 | 01/10/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599586 |
| Principal investigator 1 | Genentech, Inc. | $1,392.07 | 01/10/2025 | Non-covered Recipient Entity DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211599590 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $40,920.95 | 01/10/2025 | Non-covered Recipient Entity DURANT ET AL SIERRA EYE ASSOCIATES | ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study | No dispute reported | 06/30/2026 | 1190305073 |
| Principal investigator 1 | Janssen Research & Development, LLC | $150.00 | 01/09/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427155 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 01/09/2025 | Non-covered Recipient Entity DURANT ET AL | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175427273 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $1,000.00 | 01/08/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221798844 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $340.62 | 01/08/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | No dispute reported | 06/30/2026 | 1221798852 |
| Principal investigator 1 | Genentech, Inc. | $6,217.00 | 01/03/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655498 |
| Principal investigator 1 | Genentech, Inc. | $720.00 | 01/03/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211655509 |
| Principal investigator 1 | Genentech, Inc. | $973.00 | 01/03/2025 | Non-covered Recipient Entity SIERRA EYE ASSOCIATES | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211655540 |